Xiaofang Huang
Head of Immunoproteomics at Emergex Vaccines Holding Ltd - Vale of White Horse, ENG, UK
Xiaofang Huang's Colleagues at Emergex Vaccines Holding Ltd
Xiaofang Huang's Contact Details
N/A
Philadelphia, Pennsylvania, United States
Emergex Vaccines Holding Ltd
Xiaofang Huang's Company Details
Emergex, a clinical-stage, privately-held biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of 100% synthetic T cell Adaptive Vaccines that harness the body's natural T cell immune response to destroy pathogen-infected cells for protection against some of the world's most pressing health threats, including viral infectious diseases, such as Dengue Fever, COVID-19, pandemic Influenza, as well as serious intra-cellular bacterial infections.Emergex has a growing pipeline of innovative CD8+ T cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease. Emergex has a number of Phase I clinical trials underway, of which the most advanced programmes in development are Dengue Fever (which may also be disease-modifying for other members of the Flaviviridae virus family, such as Zika and Yellow Fever), as well as COVID-19. Other programmes in development include vaccine candidates for universal (pandemic) Influenza, Chikungunya, and a booster vaccine for Yellow Fever.Emergex's T cell Adaptive Vaccines candidates combine two proprietary technologies, [i] an empirically determined library of pathogen-derived protein fragments expressed on the surface of pathogen-infected cells (forming the MHC Class I expression "ligandome" library), and [ii] a passivated gold nanoparticle carrier system designed to deliver the synthetic peptides to the skin-resident immune system (in combination with nociception) via micro-needles to elicit a robust adaptive CD8 T cell response. With potential stability at ambient temperatures, the vaccine candidates as intended reduce the burden and logistics of vaccine administration.Find out more online at www.emergexvaccines.com.